• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Biotech Market
    Biotech News
    Biotech Stocks
    • Biotech Market
    • Biotech News
    • Biotech Stocks

    Oncolytics Biotech to Present REOLYSIN Safety Data

    Bryan Mc Govern
    Jul. 26, 2017 09:10AM PST
    Biotech Investing

    Oncolytics Biotech announced two abstracts describing both pooled safety and tolerability data and the mechanism of REOLYSIN will be presented at the European Society for Medical Oncology 2017 Congress.

    Oncolytics Biotech (TSX:ONC) (OTCQX:ONCYF) announced two abstracts describing both pooled safety and tolerability data and the mechanism of REOLYSIN will be presented at the European Society for Medical Oncology 2017 Congress.
    As quoted in the press release:

    The abstracts will be published online on the ESMO website at 3:05 ET on Wednesday, August 30.  The conference is taking place from September 8-12, 2017, in Madrid, Spain.
    “The pooled analysis of patients treated with intravenous pelareorep is the largest safety database available for this class of agents in combination with chemotherapy,” said Dr. Andres Gutierrez, Chief Medical Officer at Oncolytics Biotech. “While our efficacy in metastatic breast cancer announced earlier this year at AACR was captivating, the safety component of pelareorep increases the benefit-risk ratio of the therapy and supports its further development. We are particularly excited to present these results as other immuno-oncology agents in the same class have had limited or no experience with systemic administration.”
    The Company also announced that it has been granted an End-of-Phase 2 meeting with the United States Food and Drug Administration (FDA), taking place in August 2017. The meeting will address registration pathways for REOLYSIN® for the treatment of metastatic breast cancer, the indication for which the FDA has granted Fast Track designation. The Company expects to announce the outcome of this meeting in the fourth quarter of 2017.

    Click here to read the full press release.

    Source: www.newswire.ca

    end of phase 2 meetingchief medical officerfood and drug administrationfast track designationbreast cancer
    The Conversation (0)

    Go Deeper

    AI Powered
    Pharmaceutical Investing

    New Collaboration for Oncolytics Biotech and SOLTI

    Biotech Watchlist 2013 Update: Exciting Ideas Have Explosive Potential

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Biotech Investing Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×